Pancreatic cancer: New hopes after first line treatment

Table 1 Randomized second line studies

Ref.	Year	Study	Regimens	Patients	OS (mo)
Pelzer et al[19]	2011	CONKO-01	OFF vs BSC	23	4.8 vs 2.3
Oettle et al[6]	2014	CONKO-003	OFF vs 5-FU	76	5.9 vs 3.3
Wang-Gillam et al[45]	2015	NAPOLI 1	Nal-iri + 5-FU + LLV vs Nal-iri vs 5-FU + LLV	417	6.1 vs 4.9 vs 4.2
Ulrich-Pur et al[30]	2003		Raltitrexed + irinotecan vs raltitrexed	38	6.5 vs 4.3

BSC: Best supportive care; 5-FU: 5-fluorouracil; OS: Overall survival; LLV: L-leucovorin.

Table 2 Most significant not randomized second line studies

Ref.	Year study	Regimens	Patients	OS (mo)
Reni et al[22]	2006	Oxaliplatin + Raltitrexed	41	5.2
Demols et al[23]	2006	Oxaliplatin + Gemcitabine	33	6
Saif et al[25]	2010	Docetaxel	17	4
Yi et al[31]	2009	Irinotecan	33	6.6
Zaniboni et al[32]	2012	Folfiri	50	5
Bertocchi et al[40]	2015	Abraxane + gemcitabine	23	5

OS: Overall survival.